Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

Over the last 18 months, 3 immunotherapy combination regimens (ipilimumab + nivolumab, pembrolizumab + axitinib, and axitinib + avelumab) were approved by the US Food and Drug Administration for the first-line treatment of metastatic renal cell carcinoma (mRCC), making selection of the optimal first...

Descripción completa

Detalles Bibliográficos
Autores principales: Chau, Vincent, Bilusic, Marijo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443011/
https://www.ncbi.nlm.nih.gov/pubmed/32884346
http://dx.doi.org/10.2147/CMAR.S216605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443011/
https://www.ncbi.nlm.nih.gov/pubmed/32884346
http://dx.doi.org/10.2147/CMAR.S216605

Ejemplares similares